Close

Bristol-Myers Squibb (BMY) volatility flat at 20 into positive clinical results

June 23, 2011 8:33 AM EDT
Bristol-Myers Squibb (NYSE: BMY) is recently up 7.2% in pre-open trading following promising clinical results from stroke-preventing Eliquis. Deutsche Bank reiterated their Buy rating and $31.50 price target on BMY. Overall option implied volatility of 20 is near its six-month average according to Track Data.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Options

Related Entities

Deutsche Bank, Options